Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Concerning Trastuzumab deruxtecan & Breast cancer / Mammacarcinoma (HER2+), Trastuzumab deruxtecan (fam‑trastuzumab deruxtecan‑nxki, Enhertu) has FDA and EMA approvals for HER2‑positive and HER2‑low Breast cancer / Mammacarcinoma (HER2+), but not for triple‑negative breast cancer (TNBC) without HER2 expression (1, 3).
The Phase III Destiny-Breast04 Trial showed benefit in progression-free and overall survival in patients with HER2-low metastatic breast cancers treated with T-DXd compared to treatment of physician’s choice chemotherapy. T-DXd is the first ph…